VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, highlighting progress during the first half of 2026 and growing interest from potential pharmaceutical partners. The company’s pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
According to the press release, VERAXA plans to prioritize investment in its proprietary BiTAC platform while seeking to monetize selected non-BiTAC programs to help finance future development. The company aims to advance its lead BiTAC-TCE candidate, VXA-102, to IND/CTA readiness by early 2028.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in VERAXA’s differentiated BiTAC platform and its potential to secure strategic collaborations. The company said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
VERAXA’s BiTAC platform is designed to create bispecific T-cell engagers that redirect the immune system to kill cancer cells. The company’s pipeline also includes bispecific ADCs, which combine the targeting ability of antibodies with the potency of cytotoxic drugs. By focusing on its core BiTAC technology while monetizing non-core assets, VERAXA aims to extend its cash runway and accelerate clinical development.
For more details, the full press release is available at https://ibn.fm/xTF5q. Additional information about VERAXA can be found in the company’s newsroom at http://ibn.fm/VRXA.
